Research Article
Same Day Biopsy and Treatment of Non-Melanoma Skin Cancer in Patients with Field Cancerization: A Retrospective Chart Study
Table 3
Factors associated with treatment failure among 244 lesions.
| Variables | Treatment success (n = 221; 91%) | Treatment failure (n = 23; 9%) | value |
| Male | 178 (81%) | 20 (87%) | 0.454 ^ 1 | Age (years)1 | 73 (65–77) | 74 (68–78) | 0.331 ^ 2 | Immunocompromised | 82 (37%) | 10 (43%) | 0.550^2 | Transplant | 64 (76%) | 9 (90%) | 0.642 ^ 3 | Other | 18 (22%) | 1 (10%) | Prior NMSC count2 | 21 (11–32) | 22 (11–30) | 0.682 ^ 2 | Location5 | Face/ears/neck | 27 (77%) | 8 (23%) | 0.024 ^ 3 | Scalp | 25 (96%) | 3 (4%) | Trunk | 53 (98%) | 1 (2%) | UE | 82 (92%) | 7 (8%) | LE | 34 (89%) | 4 (11%) | Size5 | <10 mm | 97 (92%) | 9 (8%) | 0.361 ^ 3 | 10–19 mm | 95 (91%) | 9 (9%) | | >19 mm | 18 (82%) | 4 (18%) | | Missing | 11 (92%) | 1 (8%) | | Histological type5 | Benign4 | N/A | N/A | <0.001 ^ 3 | Invasive SCC | 18 (64%) | 10 (36%) | SCC in situ | 60 (88%) | 8 (12%) | BCC | 59 (92%) | 5 (8%) | AK | 56 (100%) | 0 (0%) |
|
|
BCC, basal cell carcinoma; LE, lower extremity; SCC, squamous cell carcinoma; UE, upper extremity. 1Chi squared test. 2t-test. 3Fisher exact test. 4Benign not counted in “treatment success.” 5Percentages reported are across the row.
|